A5033482846- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Thyroid Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Synthesis and biological activity
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Head and Neck Cancer Studies
- Bladder and Urothelial Cancer Treatments
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Virus-based gene therapy research
- Renal cell carcinoma treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Ovarian cancer diagnosis and treatment
- Cancer Research and Treatments
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
Providence Portland Medical Center
2020-2025
University of Saskatchewan
2025
Pfizer (United States)
2025
Oregon Health & Science University
2015-2024
Providence College
2021-2023
University of the West Indies System
2023
HealthONE
2023
Cancer Institute (WIA)
2022
Angeles Clinic and Research Institute
2019
Cedars-Sinai Medical Center
2019
In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with high rate objective response, including complete responses, among patients advanced melanoma.
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers children and adults. We evaluated the efficacy safety larotrectinib, a highly selective TRK inhibitor, adults who had tumors with these fusions.We enrolled patients consecutively prospectively identified fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into protocols: phase 1 study adults, 1-2 children, or 2 adolescents The primary end point for combined...
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast 1 through 4, platelet-derived receptor α, RET, KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).In our randomized, double-blind, multicenter progressive iodine-131, we randomly assigned 261 receive lenvatinib (at daily dose 24 mg per day 28-day cycles) 131 placebo. At the time disease...
RET mutations occur in 70% of medullary thyroid cancers, and fusions rarely other cancers. In patients with RET-altered the efficacy safety selective inhibition are unknown.
Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.
Modulation of vascular endothelial growth factor-mediated immune suppression via angiogenesis inhibition may augment the activity checkpoint inhibitors. We report results from dose-finding and initial phase II expansion a Ib/II study lenvatinib plus pembrolizumab in patients with selected advanced solid tumors.Eligible had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous head neck (SCCHN), melanoma, non-small-cell lung cancer (NSCLC), or urothelial cancer. The primary...
<h3>Importance</h3> Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. <h3>Objective</h3> To assess the efficacy and safety of avelumab, an anti–programmed death-ligand 1 agent, a cohort with previously treated recurrent or refractory cancer. <h3>Design, Setting, Participants</h3> In expansion phase 1b, open-label study (JAVELIN Solid Tumor), 125 advanced who had...
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid (MTC), and papillary cancer. No approved therapies have been designed to target RET; treatment has limited multikinase inhibitors (MKI), which can significant off-target toxicities efficacy. BLU-667 a highly potent selective RET inhibitor overcome these limitations. In vitro, demonstrated ≥10-fold increased...
Anaplastic thyroid carcinoma is an aggressive malignancy that almost always fatal and lacks effective systemic treatment options for patients with
Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of multicenter, open-label, phase 1/2 trial nivolumab ± ipilimumab (CheckMate 032; NCT01928394). We report updated results, including long-term overall survival (OS), cohort.Patients with disease progression after one to two prior chemotherapy regimens were 3:2 3 mg/kg every 2 weeks 1 plus four cycles followed by...
LBA9503 Background: mRNA-4157 is a novel mRNA-based personalized cancer vaccine which encodes up to 34 patient-specific tumor neoantigens. The open-label randomized Phase 2 mRNA-4157-P201/Keynote-942 trial met its primary endpoint of recurrence free survival (RFS) in patients with resected high-risk stage IIIB/C/D and IV melanoma. study has shown statistically significant clinically meaningful improvement RFS the combination therapy compared pembrolizumab monotherapy, reduction risk or death...
<h3>Importance</h3> Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies antitumor activity in this disease, but little is known about the of anti–programmed ligand (PD-L1) patients mesothelioma. <h3>Objective</h3> To assess efficacy safety avelumab a cohort previously treated <h3>Design, Setting, Participants</h3> Phase 1b open-label study (JAVELIN Solid Tumor)...
NTRK1, NTRK2 and NTRK3 gene fusions (NTRK fusions) occur in a range of adult cancers. Larotrectinib is potent highly selective ATP-competitive inhibitor TRK kinases has demonstrated activity patients with tumours harbouring NTRK fusions.
5533 Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report safety and activity of avelumab patients (pts) with recurrent/refractory ovarian cancer (OC; NCT01772004). Methods: Pts advanced OC unselected for PD-L1 expression received 10 mg/kg IV Q2W until progression, unacceptable toxicity, or withdrawal. Tumors were assessed every 6 wks (RECIST 1.1). Unconfirmed objective response rate (ORR), progression-free survival...
Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is novel, first-in-class, agonist CD27 antibody stimulates the pathway, which results in T-cell activation antitumor activity tumor models. This first-in-human, dose-escalation expansion study evaluated safety, pharmacology, of varlilumab patients with advanced solid tumors. Methods...
5509 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of immune response against multiple cancers. Avelumab (proposed INN) (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently being investigated clinical trials. Here we present results from cohort patients (pts) with recurrent or refractory ovarian cancer an ongoing phase Ib study (NCT01772004). Methods: Pts ECOG PS 0-1 received avelumab at 10 mg/kg Q2W....